Prediction of CK-MB Release During Otherwise Successful Stenting Procedure

Completed · Not applicable

Conditions studied: Diabetes Mellitus

In brief

Aims of this study will be to assess the difference in CFV/CFR (Coronary flow velocity/reserve) in diabetic vs. non-diabetic patients and to correlate CK-MB, TnI and HsCRP release after otherwise successful coronary stenting.

Key facts

Study ID

NCT00489242

Run by

Icahn School of Medicine at Mount Sinai

People needed

72

Starts

2003-08-01

Expected to finish

2005-09-01

Last updated by the study team

2007-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients >18 years of age
• Stable patients who will undergo PCI (intent to stent)
• Patients with de novo type B2/C lesions of native coronary vessels

You may not qualify if…

• Patients with acute myocardial infarction (Q wave or non-Q wave with CK-MB 5 times above the upper normal [80 U/L] within 72 hours)
• Patients who are in cardiogenic shock
• Patients with restenotic lesions
• Patients with type A and type B1 lesions of native coronary vessels
• Patients who require use of atherectomy devices for PCI
• Patients who have elevated CK-MB (>16 U/L) or TnI (>2ng/L) at baseline
• Patients who receive tirofiban or eptifibatide infusion within 24 hours of PCI
• Patients with known allergy to abciximab and adenosine
• Patients with platelet count <100,000 cell/mm3
• Patients who have co-morbidity which reduces life expectancy to one year
• Patients who are currently participating in another investigational drug/device study

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.